Cargando…

The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis

BACKGROUND: The Lung Immune Prognostic Index (LIPI) combines the lactate dehydrogenase (LDH) level and the derived neutrophil-to-lymphocyte ratio (dNLR). A lot of studies have shown that LDH and dNLR are associated with the prognosis of advanced non-small cell lung cancer (NSCLC) in patients treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qianning, Gong, Xiaoling, Sun, Lei, Miao, Liyun, Zhou, Yujie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340347/
https://www.ncbi.nlm.nih.gov/pubmed/35924149
http://dx.doi.org/10.3389/fonc.2022.791496
_version_ 1784760382458429440
author Zhang, Qianning
Gong, Xiaoling
Sun, Lei
Miao, Liyun
Zhou, Yujie
author_facet Zhang, Qianning
Gong, Xiaoling
Sun, Lei
Miao, Liyun
Zhou, Yujie
author_sort Zhang, Qianning
collection PubMed
description BACKGROUND: The Lung Immune Prognostic Index (LIPI) combines the lactate dehydrogenase (LDH) level and the derived neutrophil-to-lymphocyte ratio (dNLR). A lot of studies have shown that LDH and dNLR are associated with the prognosis of advanced non-small cell lung cancer (NSCLC) in patients treated with programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitors. However, previous results were inconsistent, and the conclusions remain unclear. This meta-analysis aimed to investigate the predictive value of pretreatment LDH and dNLR for NSCLC progression in patients treated with PD-1/PD-L1 inhibitors. METHODS: PubMed, Embase, and the Cochrane Library were searched by two researchers independently for related literature before March 2020. Hazard ratios (HRs) with 95% confidence intervals (CIs) for progression-free survival (PFS) and overall survival (OS) were extracted to assess the predictive value of LDH and dNLR. STATA 15. 0 was used to perform the meta-analysis. RESULTS: A total of 3,429 patients from 26 studies were included in this meta-analysis. The results revealed that high pretreatment LDH was related to poor OS (HR = 1.19, 95%CI = 1.11–1.24, p < 0.001), but not closely related to poor PFS (HR = 1.02, 95%CI = 1.00–1.04, p = 0.023 < 0.05). The pooled results for dNLR suggested that high pretreatment dNLR was related to poor OS (HR = 1.55, 95%CI = 1.33–1.80, p < 0.001) and PFS (HR = 1.33, 95%CI = 1.16–1.54, p < 0.001). CONCLUSION: Both pretreatment LDH and dNLR have the potential to serve as peripheral blood biomarkers for patients with advanced NSCLC treated with PD-1/PD-L1 inhibitors. However, more studies on LDH are needed to evaluate its predictive value for PFS in patients with NSCLC.
format Online
Article
Text
id pubmed-9340347
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93403472022-08-02 The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis Zhang, Qianning Gong, Xiaoling Sun, Lei Miao, Liyun Zhou, Yujie Front Oncol Oncology BACKGROUND: The Lung Immune Prognostic Index (LIPI) combines the lactate dehydrogenase (LDH) level and the derived neutrophil-to-lymphocyte ratio (dNLR). A lot of studies have shown that LDH and dNLR are associated with the prognosis of advanced non-small cell lung cancer (NSCLC) in patients treated with programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitors. However, previous results were inconsistent, and the conclusions remain unclear. This meta-analysis aimed to investigate the predictive value of pretreatment LDH and dNLR for NSCLC progression in patients treated with PD-1/PD-L1 inhibitors. METHODS: PubMed, Embase, and the Cochrane Library were searched by two researchers independently for related literature before March 2020. Hazard ratios (HRs) with 95% confidence intervals (CIs) for progression-free survival (PFS) and overall survival (OS) were extracted to assess the predictive value of LDH and dNLR. STATA 15. 0 was used to perform the meta-analysis. RESULTS: A total of 3,429 patients from 26 studies were included in this meta-analysis. The results revealed that high pretreatment LDH was related to poor OS (HR = 1.19, 95%CI = 1.11–1.24, p < 0.001), but not closely related to poor PFS (HR = 1.02, 95%CI = 1.00–1.04, p = 0.023 < 0.05). The pooled results for dNLR suggested that high pretreatment dNLR was related to poor OS (HR = 1.55, 95%CI = 1.33–1.80, p < 0.001) and PFS (HR = 1.33, 95%CI = 1.16–1.54, p < 0.001). CONCLUSION: Both pretreatment LDH and dNLR have the potential to serve as peripheral blood biomarkers for patients with advanced NSCLC treated with PD-1/PD-L1 inhibitors. However, more studies on LDH are needed to evaluate its predictive value for PFS in patients with NSCLC. Frontiers Media S.A. 2022-07-18 /pmc/articles/PMC9340347/ /pubmed/35924149 http://dx.doi.org/10.3389/fonc.2022.791496 Text en Copyright © 2022 Zhang, Gong, Sun, Miao and Zhou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhang, Qianning
Gong, Xiaoling
Sun, Lei
Miao, Liyun
Zhou, Yujie
The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis
title The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis
title_full The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis
title_fullStr The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis
title_full_unstemmed The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis
title_short The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis
title_sort predictive value of pretreatment lactate dehydrogenase and derived neutrophil-to-lymphocyte ratio in advanced non-small cell lung cancer patients treated with pd-1/pd-l1 inhibitors: a meta-analysis
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340347/
https://www.ncbi.nlm.nih.gov/pubmed/35924149
http://dx.doi.org/10.3389/fonc.2022.791496
work_keys_str_mv AT zhangqianning thepredictivevalueofpretreatmentlactatedehydrogenaseandderivedneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithpd1pdl1inhibitorsametaanalysis
AT gongxiaoling thepredictivevalueofpretreatmentlactatedehydrogenaseandderivedneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithpd1pdl1inhibitorsametaanalysis
AT sunlei thepredictivevalueofpretreatmentlactatedehydrogenaseandderivedneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithpd1pdl1inhibitorsametaanalysis
AT miaoliyun thepredictivevalueofpretreatmentlactatedehydrogenaseandderivedneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithpd1pdl1inhibitorsametaanalysis
AT zhouyujie thepredictivevalueofpretreatmentlactatedehydrogenaseandderivedneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithpd1pdl1inhibitorsametaanalysis
AT zhangqianning predictivevalueofpretreatmentlactatedehydrogenaseandderivedneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithpd1pdl1inhibitorsametaanalysis
AT gongxiaoling predictivevalueofpretreatmentlactatedehydrogenaseandderivedneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithpd1pdl1inhibitorsametaanalysis
AT sunlei predictivevalueofpretreatmentlactatedehydrogenaseandderivedneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithpd1pdl1inhibitorsametaanalysis
AT miaoliyun predictivevalueofpretreatmentlactatedehydrogenaseandderivedneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithpd1pdl1inhibitorsametaanalysis
AT zhouyujie predictivevalueofpretreatmentlactatedehydrogenaseandderivedneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithpd1pdl1inhibitorsametaanalysis